NAD+

Oral NMN and NR are chosen because they are accessible, well-tolerated, and have meaningful mechanistic backing even if the human clinical data is still developing. Users who care about longevity and recovery quality as part of their performance framework include them as background support rather than front-line performance compounds.

Injectable or IV NAD+ is chosen by users who want more acute elevation and are comfortable with the vasodilatory side effects as part of a deliberate protocol.

Oral precursors (NMN / NR):

• NMN: 250–1000 mg daily, morning dosing preferred.
• NR: 300–600 mg daily.
• Both are oral and do not require reconstitution.

Subcutaneous or IV NAD+:

• IV NAD+ infusions (250–1000 mg) are used in clinical longevity contexts. Require slow infusion to avoid severe flushing and chest tightness.
• Subcutaneous NAD+ (25–100 mg injected slowly) is used by self-experimenters as a less acute alternative to IV.
• Injectable NAD+ should be approached cautiously because rapid administration causes intense flushing, chest discomfort, and nausea.

Oral precursors are not felt acutely like a stimulant. The feedback from users is typically improved recovery quality, better energy across long training blocks, and subjective reduction in the “biological debt” that demanding protocols accumulate. These are real but subtle signals rather than dramatic performance changes.

Use context

NAD+ support has moved from obscure longevity research into mainstream performance and anti-aging use. The core rationale is real: NAD+ is required for the functioning of sirtuins (SIRT1/SIRT3, which regulate mitochondrial function and stress response), PARP enzymes (DNA repair), and the electron transport chain itself. Declining NAD+ with age correlates with declining mitochondrial efficiency, slower repair, and the accumulating dysfunction that looks like aging.

In performance contexts the use case is recovery, particularly the kind of cellular recovery that hard training, caloric deficit, sleep disruption, and AAS use collectively stress. It is not a compound that dramatically changes performance acutely. It is more like maintaining the cellular infrastructure that everything else depends on.

Expecting NMN or NR to feel like a stimulant or produce immediate noticeable effects. Treating IV NAD+ as a routine self-administration project without understanding the acute side effect profile. Choosing cheap, poorly characterized products for a compound where quality and precursor purity matters.

Compared with MOTS-c, NAD+ precursors address mitochondrial function from a different angle: substrate availability rather than peptide signaling. The two are complementary and sometimes stacked in comprehensive longevity protocols. Compared with creatine or ATP precursors, NAD+ operates at a deeper level of cellular energy metabolism rather than direct phosphocreatine pathway support.